Aerie Pharmaceuticals

$17.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.67 (-3.74%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AERI and other stocks, options, and ETFs commission-free!

About AERI

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.

CEO
Vicente J. Anido
Employees
365
Headquarters
Durham, North Carolina
Founded
2005
Market Cap
842.74M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
541.79K
High Today
$18.14
Low Today
$17.15
Open Price
$18.14
Volume
488.52K
52 Week High
$21.30
52 Week Low
$9.01

AERI Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, After Hours

You May Also Like

SHO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure